BAY 60-6583 Enhances the Antitumor Function of Chimeric Antigen Receptor-Modified T Cells Independent of the Adenosine A2b Receptor
Chimeric antigen receptor (CAR) T cells are powerful in eradicating hematological malignancies, but their efficacy is limited in treating solid tumors. One of the barriers is the immunosuppressive response induced by immunomodulatory signaling pathways. Pharmacological targeting of these immunosuppr...
Main Authors: | Jiaxing Tang, Yan Zou, Long Li, Fengping Lu, Hongtao Xu, Pengxuan Ren, Fang Bai, Gabriele Niedermann, Xuekai Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.619800/full |
Similar Items
-
Evaluation of the Effects A2B Adenosine Receptor-Agonist (BAY 60–6583) in Induction of Apoptosis in ACHN Renal Cancer Cell Line
by: Abdol-Vahab Shafiee, et al.
Published: (2018-04-01) -
Galunisertib enhances chimeric antigen receptor-modified T cell function
by: Zhixiong Wang, et al.
Published: (2020-06-01) -
CD137 Co-Stimulation Improves The Antitumor Effect Of LMP1-Specific Chimeric Antigen Receptor T Cells In Vitro And In Vivo
by: Tang X, et al.
Published: (2019-11-01) -
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
by: Erhao Zhang, et al.
Published: (2018-01-01) -
Novel positive allosteric modulators of A2B adenosine receptor acting as bone mineralisation promoters
by: Elisabetta Barresi, et al.
Published: (2021-01-01)